434
Views
3
CrossRef citations to date
0
Altmetric
Article Addendum

Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation

, &
Pages 40-42 | Received 04 Apr 2012, Accepted 10 May 2012, Published online: 01 Apr 2012

Abstract

With the introduction of nonmyeloablative conditioning, hematopoietic cell transplantation (HCT) has become a viable treatment option for patients who due to age or comorbidities are ineligible for high dose conditioning. However, relapse and toxicities are still major problems in HCT. Radioimmunotherapy (RIT)-based conditioning is a promising approach that has the ability to specifically target radiation to hematopoietic cells. The most widely investigated isotopes are the β-emitters, but because of long path lengths and low linear energy transfer, α-emitters which have more favorable physical characteristics, might prove to be a better alternative. In the current study we have investigated the efficacy and safety of α-emitter based RIT as the only form of conditioning in a preclinical model of canine allogeneic HCT.

This article refers to:

A major dilemma in allogeneic hematopoietic cell transplantation (HCT) is that the benefit gained by intensifying the conditioning regimen to reduce relapse rates, is negated by increased regimen related toxicity and mortality. The introduction of nonmyeloablative conditioning, where external total body (TBI) irradiation is decreased from 12 to 2 Gy, has reduced regimen related toxicity significantly.Citation1,Citation2 However, as toxicity and relapse are still major problems in HCT, there is a desire to further decrease the toxicity associated with external γ-radiation and possibly increase the radiation dose deposited in target tissues without increasing exposure of surrounding tissues. Radioimmunotherapy (RIT) is a treatment strategy that targets radiation precisely to the desired tissues. The efficacy and safety of RIT in delivering targeted radiation therapy has been demonstrated in several clinical settings. The most widely used isotopes for RIT are the β-emitters, and they have previously been used to augment conventional external γ-radiation in a variety of conditioning regimens in allogeneic HCT.Citation3-Citation6 β-emitters, such as yttrium-90 (90Y), rhenium-188 and iodine-131 (131I), are characterized by low linear energy transfer and long path lengths (800–5000 µm). Characteristics like these make β-emitters ideal for the treatment of bulky, poorly perfused tumors. However, when targeting hematopoietic cells or malignancies, where tissues are well perfused, β-emitters induce off-target toxicity as significant amounts of radiation are deposited in the surrounding healthy tissues.Citation7

Alternative sources of radiation are the less explored α-emitters. They have short path lengths (40–90 µm) which only span a few cell diameters in vivo, hereby limiting radiation exposure of surrounding tissues. Furthermore, α-emitters also have up to 400 times higher linear energy transfer, which combined with a limited ability of cells to repair α-radiation induced damage, results in a superior relative biological effectiveness.Citation8-Citation10

In an effort to limit radiation-induced toxicity and replace external γ-radiation, we have investigated the safety and efficacy of α-emitter-based RIT, as the sole form of conditioning prior to allogeneic HCT in a preclinical canine model. In our initial experiments we used the α-emitter bismuth-213 (213Bi) conjugated to monoclonal antibodies (mAb) against CD45. CD45 is expressed in high numbers on virtually all non-malignant and malignant hematopoietic cells through all stages of maturation,Citation11,Citation12 and was chosen as antigen because of its ability to effectively target T-cells and natural killer (NK) cells responsible for rejectionCitation13-Citation15 and possibly eradicate minimal residual disease if present. Although dog leukocyte antigen (DLA) HCT using 1.0–5.9 mCi/kg 213Bi labeled anti-CD45 mAb was successful, with low rejection rates, minimal toxicity and durable long-term donor chimerism in the mononuclear cell (MNC) compartment,Citation16,Citation17 several factors precluded further investigation and translation into clinical trials. Logistics with 213Bi were cumbersome due to its short half-life (t½) (46 min). To deliver the planned doses, three to eight injections over two successive days were necessary, to avoid significant decay of the isotope before treatment. Furthermore, the availability of the 213Bi parent compound actinium-225 (225Ac) was limited and costs excessively high. As an alternative, we investigated the α-emitter astatine-211 (211At). 211At has a t½ (7.2 h) that allows treatments to be administered as one injection and is locally available in sufficient amounts and at a cost that permits upscaling to clinical trials. Furthermore, as part of the transition from 213Bi to 211At, murine studies demonstrated that the radiation dose from 50 µCi 211At deposited in the spleen was almost 2-fold higher than from 500 µCi 213Bi without a concomitant increase in toxicity, suggesting a superior nonhematologic toxicity profile of 211At-antiCD45 mAb.Citation18 Canine biodistribution was favorable,Citation19 and in dose-finding studies, treatment with 0.1–0.62 mCi/kg without HCT rescue demonstrated dose-dependent myelosuppression followed by autologous recovery.Citation20 Encouraged by these results DLA-identical HCT studies with a single dose of 1.6–6.3 mCi/kg 211At loaded on to 0.5 mg/kg anti-CD45 mAb were conducted.Citation20 Depth of granulocyte, lymphocyte and platelet nadirs were dose-dependent, and more profound than with 2 Gy external γ-radiationCitation21 or 213Bi-anti-CD45 mAb.Citation16,Citation17 All dogs had long-term engraftment. Apart from the dog treated with the lowest dose (1.6 mCi/kg), which was euthanized with stable 5% donor chimerism in MNC after 18 weeks, all dogs had durable donor chimerism in the MSC compartment (19–58%) at 40–53 weeks post-transplant. Toxicity was mild, and consisted mainly of transient elevations in liver function enzymes and subclinical hypothyroidism in two dogs, which could not be directly attributed to radiation exposure.

Our studies show that conditioning with 211At-anti-CD45-based RIT in HCT is safe and has the ability to induce durable high level donor chimerism. There was low toxicity and more myelo- and lymphosuppression than what is observed with 2 Gy TBI in the same model. The data suggest that conditioning with 211At-anti-CD45 based RIT could expand the nonmyeloablative approach to patients who cannot endure conventional high dose TBI, but where the nonmyeloablative approach with only 2 Gy TBI is not sufficient for disease control or engraftment. In haploidentical donor HCT, where significant conditioning is required to overcome the immunological barriers and establish durable chimerism,Citation22 we have previously conducted a pilot study with 213Bi-anti-CD45 based conditioning in the DLA-haploidentical HCT model.Citation23 Although initially successful, with four of six dogs acquiring sustained donor chimerism, survival was short due to toxicity. In this setting, an 211At-based RIT regimen may also prove superior due to a more profound myelosuppression and favorable nonhematologic toxicity profile.

Prior to the transition from 213Bi to 211At, we also explored the possibility of further minimizing toxicity, by targeting radiation specifically toward TCRαβ+ T-cells, which have shown to be of particular importance for rejection.Citation14 Of 11 dogs conditioned with 1.1–5.6 mCi/kg 213Bi-anti-TCRαβ mAb prior to DLA-identical HCT, four conditioned with less than 1.5 mCi/kg rejected their graft and had autologous recovery. Compared with the studies using anti-CD45 mAb, a steeper decline in peripheral lymphocyte counts was observed, and in dogs that did not reject long-term donor chimerism was stable, but at a lower level (MNC, 3–40%). Although the low level chimerism observed following anti-TCRαβ-based RIT may not be sufficient to cure malignant disease, it may be suitable for the treatment of nonmalignant diseases such as hemoglobinopathies, immunodeficiencies, inborn errors of metabolism, as well as in gene transfer studies where full donor chimerism is not a requirement for cure but the long-term toxicities associated with HCT conditioning are a major concern.

α-emitter-anti-TCRαβ-RIT-based HCT may also play a role in solid organ transplantations, where toxicity due to lifelong immunosuppressive treatment is associated with significant morbidity. Canine studies have demonstrated that mixed chimerism achieved through a HCT from the organ donor induces tolerance toward the donor organ, enabling long-term survival of kidneys and vascularized composite skin and muscle grafts without pharmacological immunosuppressive treatment.Citation24,Citation25

A novel avenue of research where 211At may prove useful is radiovirotherapy (RVT) (reviewed by Touchefeu).Citation26 The principle of RVT is to deliver radioisotopes into virally infected malignant cells. The most common approach is to use oncolytic viruses that have been genetically engineered to express the thyroidal sodium/iodide symporter (NIS). Although the main physiological function of NIS is to transport into iodine thyroid follicular cells, it has also been demonstrated to efficiently transport 211At, with an approximately 15-fold higher tumor absorbed dose compared with 131I in tumor cell line experiments.Citation27 Several in vitro and in vivo animal studies have already demonstrated efficient tumor killing by NIS 211At-based RVT which, when combined with the 211At short path length that limits damage to non-target tissues, may make 211At a highly attractive isotope for clinical trials.

In conclusion, our studies demonstrate that conditioning with α-emitter-based RIT in allogeneic HCT is feasible and safe. They provide a platform for future investigation of α-emitter-based conditioning, and a basis for the translation of α-emitter-based therapy in a wide variety of clinical trials.

Abbreviations:
225Ac=

actinium-225

211At=

astatine-211

213Bi=

bismuth-213

DLA=

dog leukocyte antigen

HCT=

hematopoietic cell transplantation

131I=

iodine-131

mAb=

monoclonal antibodies

MNC=

mononuclear cell

NK=

natural killer

RIT=

radioimmunotherapy

RVT=

radiovirotherapy

NIS=

sodium/iodide symporter

TBI=

total body irradiation

90Y=

yttrium-90

Acknowledgments

B.K. drafted and revised the manuscript, Y.C. revised the manuscript and B.M.S. conceived, drafted and revised the manuscript. The authors declare no conflicts of interest.

References

  • McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97:3390 - 400; http://dx.doi.org/10.1182/blood.V97.11.3390; PMID: 11369628
  • Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101:1620 - 9; http://dx.doi.org/10.1182/blood-2002-05-1340; PMID: 12393457
  • Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54:829 - 33; http://dx.doi.org/10.1097/00007890-199211000-00012; PMID: 1440849
  • Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001; 98:565 - 72; http://dx.doi.org/10.1182/blood.V98.3.565; PMID: 11468151
  • Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009; 114:5444 - 53; http://dx.doi.org/10.1182/blood-2009-03-213298; PMID: 19786617
  • Schulz AS, Glatting G, Hoenig M, Schuetz C, Gatz SA, Grewendorf S, et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 2011; 117:4642 - 50; http://dx.doi.org/10.1182/blood-2010-06-284349; PMID: 21325170
  • Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody, Immunoconjugates, and Radiopharmaceuticals 1991; 4:85 - 97
  • Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res 1991; 128:204 - 9; http://dx.doi.org/10.2307/3578139; PMID: 1947017
  • Dadachova E. Cancer therapy with alpha-emitters labeled peptides. Semin Nucl Med 2010; 40:204 - 8; http://dx.doi.org/10.1053/j.semnuclmed.2010.01.002; PMID: 20350629
  • Kennel SJ, Stabin M, Roeske JC, Foote LJ, Lankford PK, Terzaghi-Howe M, et al. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res 1999; 151:244 - 56; http://dx.doi.org/10.2307/3579935; PMID: 10073661
  • Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med 1980; 152:842 - 52; http://dx.doi.org/10.1084/jem.152.4.842; PMID: 6968338
  • Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol 1983; 79:546 - 52; PMID: 6188365
  • Nakamura H, Gress RE. Graft rejection by cytolytic T cells. Specificity of the effector mechanism in the rejection of allogeneic marrow. Transplantation 1990; 49:453 - 8; http://dx.doi.org/10.1097/00007890-199002000-00042; PMID: 2305471
  • Kikly K, Dennert G. Evidence for a role for T cell receptors (TCR) in the effector phase of acute bone marrow graft rejection. TCR V beta 5 transgenic mice lack effector cells able to cause graft rejection. J Immunol 1992; 149:3489 - 94; PMID: 1431119
  • Raff RF, Sandmaier BM, Graham T, Loughran TP Jr., Pettinger M, Storb R. “Resistance” to DLA-nonidentical canine unrelated marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol 1994; 22:893 - 7; PMID: 8062888
  • Sandmaier BM, Bethge WA, Wilbur DS, Hamlin DK, Santos EB, Brechbiel MW, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002; 100:318 - 26; http://dx.doi.org/10.1182/blood-2001-12-0322; PMID: 12070043
  • Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, et al. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation 2004; 78:352 - 9; http://dx.doi.org/10.1097/01.TP.0000128853.62545.B2; PMID: 15316362
  • Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the α-emitting radionuclides bismuth-213 or astatine-211. Cancer Res 2009; 69:2408 - 15; http://dx.doi.org/10.1158/0008-5472.CAN-08-4363; PMID: 19244101
  • Wilbur DS, Chyan M-K, Nakamae H, Chen Y, Hamlin DK, Santos EB, et al. Reagents for astatination of Biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. Bioconjug Chem 2012; 23:409 - 20; http://dx.doi.org/10.1021/bc200401b; PMID: 22296587
  • Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur DS, et al. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 2012; 119:1130 - 8; http://dx.doi.org/10.1182/blood-2011-09-380436; PMID: 22134165
  • Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89:3048 - 54; PMID: 9108426
  • Chen Y, Fukuda T, Thakar MS, Kornblit BT, Storer BE, Santos EB, et al. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy 2011; 13:1269 - 80; http://dx.doi.org/10.3109/14653249.2011.586997; PMID: 21846291
  • Nakamae H, Kerbauy FR, Wilbur DS, Bethge W, Hamlin DK, Santos EB, et al. Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation. Transplantation 2010; 89:1336 - 40; http://dx.doi.org/10.1097/TP.0b013e3181d98c3d; PMID: 20351629
  • Kuhr CS, Allen MD, Junghanss C, Zaucha JM, Marsh CL, Yunusov M, et al. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation 2002; 73:1487 - 92; http://dx.doi.org/10.1097/00007890-200205150-00020; PMID: 12023629
  • Mathes DW, Hwang B, Graves SS, Edwards J, Chang J, Storer BE, et al. Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras. Transplantation 2011; 92:1301 - 8; http://dx.doi.org/10.1097/TP.0b013e318237d6d4; PMID: 22082819
  • Touchefeu Y, Franken P, Harrington KJ. Radiovirotherapy: Principles and prospects in oncology. Current Pharmceutical Design 2012; 18:3313 - 20; PMID: 22397732
  • Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Pötter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2002; 29:842 - 54; http://dx.doi.org/10.1007/s00259-002-0784-7; PMID: 12111124

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.